Literature DB >> 22009735

Toxic megacolon.

Daniel M Autenrieth1, Daniel C Baumgart.   

Abstract

Toxic megacolon represents a dreaded complication of mainly inflammatory or infectious conditions of the colon. It is most commonly associated with inflammatory bowel disease (IBD), i.e., ulcerative colitis or ileocolonic Crohn's disease. Lately, the epidemiology has shifted toward infectious causes, specifically due to an increase of Clostridium difficile-associated colitis possibly due to the extensive (ab)use of broad-spectrum antibiotics. Other important infectious etiologies include Salmonella, Shigella, Campylobacter, Cytomegalovirus (CMV), rotavirus, Aspergillus, and Entameba. Less frequently, toxic megacolon has been attributed to ischemic colitis, collagenous colitis, or obstructive colorectal cancer. Toxic colonic dilatation may also occur in hemolytic-uremic syndrome (HUS) caused by enterohemorrhagic or enteroaggregative Escherichia coli O157 (EHEC, EAEC, or EAHEC). The pathophysiological mechanisms leading to toxic colonic dilatation are incompletely understood. The main characteristics of toxic megacolon are signs of systemic toxicity and severe colonic distension. Diagnosis is made by clinical evaluation for systemic toxicity and imaging studies depicting colonic dilatation. Plain abdominal imaging is still the most established radiological instrument. However, computed tomography scanning and transabdominal intestinal ultrasound are promising alternatives that add additional information. Management of toxic megacolon is an interdisciplinary task that requires close interaction of gastroenterologists and surgeons from the very beginning. The optimal timing of surgery for toxic megacolon can be challenging. Here we review the latest data on the pathogenesis, clinical presentation, laboratory, and imaging modalities and provide algorithms for an evidence-based diagnostic and therapeutic approach.

Entities:  

Mesh:

Year:  2012        PMID: 22009735     DOI: 10.1002/ibd.21847

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  30 in total

1.  Fecal Microbiota Transplant for Clostridium difficile Colitis-Induced Toxic Megacolon.

Authors:  S P Costello; A Chung; J M Andrews; R J Fraser
Journal:  Am J Gastroenterol       Date:  2015-05       Impact factor: 10.864

2.  In-hospital mortality for toxic megacolon.

Authors:  Rachele Ciccocioppo; Gino Roberto Corazza
Journal:  Intern Emerg Med       Date:  2018-08-02       Impact factor: 3.397

Review 3.  Pediatric ulcerative colitis: a practical guide to management.

Authors:  Brian P Regan; Athos Bousvaros
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

4.  Incidence, features, in-hospital outcomes and predictors of in-hospital mortality associated with toxic megacolon hospitalizations in the United States.

Authors:  Rajkumar Doshi; Jiten Desai; Yash Shah; Dean Decter; Shreyans Doshi
Journal:  Intern Emerg Med       Date:  2018-06-12       Impact factor: 3.397

Review 5.  Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis.

Authors:  G Pellino; D S Keller; G M Sampietro; M Carvello; V Celentano; C Coco; F Colombo; A Geccherle; G Luglio; M Rottoli; M Scarpa; G Sciaudone; G Sica; L Sofo; R Zinicola; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-03-02       Impact factor: 3.781

6.  Toxic megacolon from fulminant Clostridium difficile infection induced by topical silver sulphadiazine.

Authors:  Christopher B Tan; Dhyan Rajan; Mitanshu Shah; Shadab Ahmed; Lester Freedman; Kaleem Rizvon; Paul Mustacchia
Journal:  BMJ Case Rep       Date:  2012-08-08

Review 7.  Diagnosis and management of inflammatory bowel disease in children.

Authors:  Stephanie B Oliveira; Iona M Monteiro
Journal:  BMJ       Date:  2017-05-31

8.  Clostridioides difficile infection damages colonic stem cells via TcdB, impairing epithelial repair and recovery from disease.

Authors:  Steven J Mileto; Thierry Jardé; Kevin O Childress; Jaime L Jensen; Ashleigh P Rogers; Genevieve Kerr; Melanie L Hutton; Michael J Sheedlo; Sarah C Bloch; John A Shupe; Katja Horvay; Tracey Flores; Rebekah Engel; Simon Wilkins; Paul J McMurrick; D Borden Lacy; Helen E Abud; Dena Lyras
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-20       Impact factor: 11.205

9.  Lizhong decoction ameliorates ulcerative colitis in mice via modulating gut microbiota and its metabolites.

Authors:  Junfeng Zou; Yumeng Shen; Mengjun Chen; Zhimiao Zhang; Suwei Xiao; Chen Liu; Yue Wan; Lei Yang; Shu Jiang; Erxin Shang; Dawei Qian; Jinao Duan
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-17       Impact factor: 4.813

Review 10.  The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives.

Authors:  Ian Arnott; Gerhard Rogler; Jonas Halfvarson
Journal:  Inflamm Intest Dis       Date:  2018-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.